Clinical Report: Orthokeratology: What’s on the Horizon?
Overview
Orthokeratology (ortho-k) is advancing with innovations in lens materials and designs, improving patient outcomes and practitioner efficiency. Combination therapy with low-dose atropine has shown to enhance myopia control, particularly in high-risk children, while the potential for ortho-k in treating hyperopia and presbyopia is being explored.
Background
Ortho-k has been a significant treatment option for myopia control since the 1960s, and its relevance is increasing as myopia prevalence rises globally. The ability to customize ortho-k lenses using advanced corneal mapping enhances treatment efficacy. Understanding the future directions of ortho-k is crucial for optimizing patient care and addressing diverse refractive needs.
Data Highlights
No numerical data available in the source material.
Key Findings
Verify and adjust the percentage for myopia progression based on source material.Clinical Implications
Practitioners should consider ortho-k as a first-line treatment for myopia control, especially in children at high risk for rapid progression. The integration of combination therapy with atropine may enhance treatment outcomes, necessitating careful patient selection and expectation management.
Conclusion
The future of ortho-k is promising, with ongoing advancements likely to improve treatment efficacy for a broader range of refractive errors. Continued research and innovation will be essential in optimizing patient care.
References
- Wallace-Tucker A, Contact Lens Spectrum, 2025 -- Orthokeratology: What’s on the Horizon?
- Myopia Institute, 2025 -- IMI Interventions for Controlling Myopia Onset and Progression
- JAMA Ophthalmology, 2025 -- Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control
- Contact Lens Spectrum — orthokeratology today
- Contact Lens Spectrum — ORTHOKERATOLOGY TODAY
- Contact Lens Spectrum — Orthokeratology Today
- Contact Lens Spectrum - Orthokeratology Today
- Contact Lens Spectrum - orthokeratology today
- Contact Lens Spectrum - ORTHOKERATOLOGY TODAY
- IMI Interventions for Controlling Myopia Onset and Progression 2025 - Myopia Institute
- Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control: A Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
- Incidence of microbial keratitis associated with overnight orthokeratology: a multicenter collaborative study - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.